The overall R&D expense rate of the pharmaceutical industry continues to rise, and these high-input pharmaceutical companies have received intensive institutional research

【Pharmaceutical Network Industry News】Recently, Tianfeng Securities released a research report that the overall R&D expense ratio of the pharmaceutical industry continued to increase, from 3.
63% in 2020 to 3.
90%
in 2021.

Entering 2022, from the disclosed data, the overall research and development investment of the pharmaceutical industry is still rising, and the research and development expenses of many pharmaceutical companies have increased significantly in the first half of the year, such as in the field of traditional Chinese medicine, more than 70% of the 73 A-share Chinese medicine enterprises have increased
their research and development expenses year-on-year.

Among them, more than 10 pharmaceutical companies such as Tibet Pharmaceutical, Zuoli Pharmaceutical and Huluwa increased by more than 50%
year-on-year.

It is worth noting that while pharmaceutical companies with high R&D investment have gained market attention, many companies have also received intensive research
from institutions in the near future.

For example, Health Yuan was surveyed
by 38 institutions on September 7, 2022.

The pharmaceutical company has always adhered to the strategic basis of scientific and technological innovation, with the strategic goal of building a high-barrier complex preparation technology platform, and strives to gradually grow into an innovative pharmaceutical enterprise
with industry influence under the two-wheel drive of innovation and high-barrier technology platform.

In the first half of this year, the total R&D investment of Healthy Yuan was 805 million yuan, an increase of 15.
39% over the previous year, accounting for 9.
39%
of the total operating income.

According to the investor relations activity table disclosed by Baicheng Pharmaceutical on June 24, 2022, the company was surveyed
by six institutions from June 21 to June 24.

The pharmaceutical company is a drug research and development technology service enterprise combining imitation and innovation, and its main business includes entrusted research and development services (including pharmaceutical research and clinical services), the transformation of independent research and development technology achievements, equity sharing, CDMO business, etc
.

According to the report, Baicheng Pharmaceutical invested 44.
014 million yuan in research and development expenses in the first quarter of 2022, an increase of 263.
32%
over the same period of the previous year.

Yiling Pharmaceutical released the news at the end of August 2022, from 21:00 pm on August 25, 2022 (Thursday) to 11:00 am on August 26, 2022 (Friday), the company received research
from Guosheng Securities and other institutions.

In the first half of 2022, Yiling Pharmaceutical's R&D investment was 374 million yuan, accounting for 4.
03%
of operating income.

The company actively promotes the innovation of traditional Chinese medicine, creates an innovative Chinese medicine evidence chain of "three combinations" of traditional Chinese medicine theory, human experience and clinical trials, and practices a new model
of traditional Chinese medicine innovation and transformation that integrates "theory + clinical + new drugs + experiments + evidence".

Mindray Medical said in a recent institutional survey that the company has always adhered to R&D innovation strategically, and will maintain a 10% R&D investment ratio in the past and the future, of which chemiluminescence, ultra-high-end ultrasound, minimally invasive surgery and other businesses will maintain a super-proportion investment
.

By the end of the second quarter, the company had applied for a total of 7955 patents, including 5708 invention patents
.

In 2021, the company invested 2.
726 billion yuan in research and development, an increase of 30.
08% year-on-year, faster than the growth of
revenue and profit.

It can be seen that the above-mentioned subdivision tracks of the pharmaceutical companies that have been intensively investigated are diverse, involving traditional Chinese medicine, CXO, innovative drugs, medical devices and other fields
.

The industry believes that from the perspective of the long-term development of the industry, in the context of the normalization of collection and collection, medical insurance control costs, etc.
, the pharmaceutical industry in fact, no matter which subdivision track, innovation will be the main theme of its development, especially for innovative drug companies, in the eyes of the industry, with the acceleration of the commercialization process of innovative drugs, China's innovative pharmaceutical companies are moving towards a new stage of development, with the survival of the fittest, the future research and development capabilities, cash flow support enterprises will stand out
。
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.